YC Biotech and XinLe Community Health Care Group have officially joined forces to advance breast cancer screening, celebrating their partnership with a signing banquet at the renowned “Daddy’s Kitchen” restaurant in Yonghe District. This collaboration will bring cutting-edge breast cancer methylation testing technology to multiple clinics within the XinLe network, offering patients a more precise and accessible early detection method.
With a strong reputation in Taiwan’s biotechnology industry, YC Biotech and EG BioMed are recognized for their groundbreaking research and high-quality medical innovations. EG BioMed, in particular, has been honored with the 18th National Innovation Award for its pioneering work in methylation cancer testing, further reinforcing the reliability and clinical value of its technology. YC Biotech remains committed to delivering medical solutions that enhance healthcare outcomes and improve quality of life.
The event provided an opportunity for physicians to engage in in-depth discussions with YC Biotech representatives, exchanging insights on the practical applications of breast cancer methylation testing. Their enthusiasm and constructive feedback will play a crucial role in refining the implementation of this technology in clinical practice.
XinLe Community Health Care Group expressed confidence that this strategic partnership will elevate its diagnostic capabilities and strengthen its position as a leader in the healthcare industry. By integrating advanced testing into its services, the group aims to provide more comprehensive and professional breast cancer screening options, ultimately improving patient care and early detection efforts.
This collaboration marks an important milestone in the adoption of next-generation cancer detection technologies, reinforcing the commitment of YC Biotech and XinLe Community Health Care Group to advancing precision medicine and enhancing healthcare services.
